AU2021210029A1 - Anti-LAG3 monoclonal antibody, and preparation method therefor and use thereof - Google Patents

Anti-LAG3 monoclonal antibody, and preparation method therefor and use thereof Download PDF

Info

Publication number
AU2021210029A1
AU2021210029A1 AU2021210029A AU2021210029A AU2021210029A1 AU 2021210029 A1 AU2021210029 A1 AU 2021210029A1 AU 2021210029 A AU2021210029 A AU 2021210029A AU 2021210029 A AU2021210029 A AU 2021210029A AU 2021210029 A1 AU2021210029 A1 AU 2021210029A1
Authority
AU
Australia
Prior art keywords
lag3
seq
monoclonal antibody
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021210029A
Other languages
English (en)
Inventor
Honglin HE
Wei-Dong Jiang
Ge Song
Hui XIAO
Xu Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Original Assignee
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biopharmaceutical Co Ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Henlius Biopharmaceutical Co Ltd
Publication of AU2021210029A1 publication Critical patent/AU2021210029A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021210029A 2020-01-21 2021-01-19 Anti-LAG3 monoclonal antibody, and preparation method therefor and use thereof Pending AU2021210029A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010069008 2020-01-21
CN202010069008.9 2020-01-21
PCT/CN2021/072610 WO2021147837A1 (zh) 2020-01-21 2021-01-19 抗lag3单克隆抗体及其制备方法和应用

Publications (1)

Publication Number Publication Date
AU2021210029A1 true AU2021210029A1 (en) 2022-09-01

Family

ID=76993109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021210029A Pending AU2021210029A1 (en) 2020-01-21 2021-01-19 Anti-LAG3 monoclonal antibody, and preparation method therefor and use thereof

Country Status (10)

Country Link
US (1) US20230074657A1 (cg-RX-API-DMAC10.html)
EP (1) EP4095159A4 (cg-RX-API-DMAC10.html)
JP (1) JP7692918B6 (cg-RX-API-DMAC10.html)
KR (1) KR20220131279A (cg-RX-API-DMAC10.html)
CN (1) CN114945595A (cg-RX-API-DMAC10.html)
AU (1) AU2021210029A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013544A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165211A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021147837A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202208339B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
WO2023138677A1 (en) * 2022-01-24 2023-07-27 Crown Bioscience Inc. (Taicang) Novel anti-lag3 antibodies and derivative products
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US20190330336A1 (en) * 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
SI4339615T1 (sl) 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
UA128387C2 (uk) * 2017-04-05 2024-07-03 Ф. Хоффманн-Ля Рош Аг Антитіло до lag3
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
CN110204614B (zh) 2018-02-28 2022-07-12 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN110305215B (zh) 2018-03-20 2023-11-03 基石药业 新型抗lag-3抗体多肽
CN110343179B (zh) 2018-04-02 2024-03-08 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN110172099B (zh) 2018-08-16 2020-03-03 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途

Also Published As

Publication number Publication date
EP4095159A1 (en) 2022-11-30
EP4095159A4 (en) 2024-03-20
CA3165211A1 (en) 2021-07-29
US20230074657A1 (en) 2023-03-09
JP7692918B2 (ja) 2025-06-16
ZA202208339B (en) 2023-11-29
JP7692918B6 (ja) 2025-07-17
KR20220131279A (ko) 2022-09-27
JP2023510982A (ja) 2023-03-15
BR112022013544A2 (pt) 2022-09-06
WO2021147837A1 (zh) 2021-07-29
CN114945595A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
CN109563172B (zh) 抗tim-3抗体
KR102132100B1 (ko) Pd-1 항체
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR102114562B1 (ko) 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민
AU2025202283A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
KR20220131279A (ko) 항lag3단일 클론 항체 및 그 제조 방법과 응용
CN110267988A (zh) 用于与抗pd-1抗体组合的抗tim-3抗体
AU2017230091B2 (en) Activin type 2 receptor binding proteins and uses thereof
US20220119520A1 (en) Anti-cd47 antibody and application thereof
US12428482B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
KR102920224B1 (ko) 인간화 항-VEGF Fab 항체 단편 및 이의 용도
KR20180040138A (ko) 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
HK1255195A1 (en) Pd-1 antibodies
WO2021217893A1 (zh) 结合tigit抗原的抗体及其制备方法与应用
US20250019436A1 (en) Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof
KR102920217B1 (ko) 인간화 항-vegf 단클론 항체
KR20210113635A (ko) 재조합 항인간 pd-1 항체 및 이의 적용
TW202241509A (zh) Anti-pd-1抗體及其用途
KR20220087457A (ko) Lif에 특이적인 결합 분자 및 이의 용도
CN114656565B (zh) 一种抗pd-l1抗体及其应用
US20250215100A1 (en) Antigen binding protein targeting cd40, and preparation therefor and use thereof
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
RU2745560C2 (ru) 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака
HK40079690A (en) Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof
CN116813769A (zh) 一种靶向cd47的单克隆抗体及其应用